Halper Sadeh LLC Launches Investigations into ITOS and KLG Shareholder Rights Halper Sadeh LLC, a prominent investor rights law firm, is probing potential federal securities law violations concerning ITOS and KLG, advocating for shareholder interests.

Halper Sadeh LLC Launches Investigations into ITOS and KLG Shareholder Rights #United_States #New_York #Halper_Sadeh #KLG #ITOS

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right iTeos Therapeutics (NASDAQ: ITOS) has announced a definitive merger agreement to be acquired by Concentra Biosciences in a significant transaction. The deal values iTeos at $10.047 per share in cash, plus a contingent value right (CVR).The CVR includes 100% of iTeos' closing net cash exceeding $475 million and 80% of proceeds from any product candidate dispositions within six months post-closing. The transaction, unanimously approved by iTeos' board, requires tender of majority shares and minimum $475 million net cash at closing. The deal is expected to close in Q3 2025.

#ITOS iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

www.stocktitan.net/news/ITOS/i-teos-therape...

iTeos Therapeutics Winds Down Operations: Key Assets EOS-984 and EOS-215 Up for Sale iTeos plans complete shutdown while exploring sales of valuable assets including EOS-984 and obesity program. Learn what this means for shareholders. Get details.

#ITOS iTeos Therapeutics Announces Its Intention to Wind Down Operations

www.stocktitan.net/news/ITOS/i-teos-therape...

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients iTeos Therapeutics (NASDAQ: ITOS) reported disappointing topline results from the GALAXIES Lung-201 Phase 2 study evaluating belrestotug + dostarlimab combination in first-line PD-L1 high non-small cell lung cancer (NSCLC). While the study showed improvements in objective response rate (ORR), it failed to meet criteria for meaningful progression-free survival improvements. Additionally, interim analysis of GALAXIES H&N-202 Phase 2 trial showed below-threshold results in head and neck cancer.Following these results, iTeos and GSK have decided to terminate the belrestotug development program and end their collaboration. The company is halting all belrestotug-containing cohorts and new enrollment in the GALAXIES Lung-301 Phase 3 trial. iTeos has engaged TD Cowen to explore strategic alternatives to maximize shareholder value.

#ITOS iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

www.stocktitan.net/news/ITOS/i-teos-reports...

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through

#ITOS iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/ITOS/i-teos-reports...

Can iTeos' $655M War Chest Deliver on Its Promising Cancer Immunotherapy Pipeline? iTeos maintains runway through 2027 with $655M cash despite wider losses, with multiple clinical readouts expected in 2025 for its immunotherapy pipeline.

#ITOS iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/ITOS/i-teos-reports...

iTeos Unveils Ambitious 2025 Cancer Drug Pipeline: Multiple Phase 2 Readouts, $684M Cash Runway iTeos Therapeutics advances TIGIT program with 400+ patient trials in lung and head & neck cancers. Strong $684M cash position funds operations through 2027.

#ITOS iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

www.stocktitan.net/news/ITOS/i-teos-announc...

#ITOS iTeos to Participate in Upcoming Investor Conferences

www.stocktitan.net/news/ITOS/i-teos-to-part...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#UVIX, #PANW, #ITOS, #CORZ, #ANF

#OptionFlow #OptionsTrading #Trading

BREAKING NEWS: ( NASDAQ: #ITOS ) iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

#StockMarket #News